

## Disclosures

### Personal Commercial (4)

| Company Name                  | Relationship Category  | Compensation Level       | Topic Area(s)                                       |
|-------------------------------|--|--------------------------|---|
| <i>Self</i>                   |  |                          |   |
| Amgen Inc.                    | Consultant Fees/Honoraria  | Modest (< \$5,000)       |   |
| Applied Clinical Intelligence | Data Safety Monitoring Board   | Modest (< \$5,000)       | <a href="#">Invasive CV Angio and Interventions</a> |
| Prime Therapeutics            | Consultant Fees/Honoraria  | Modest (< \$5,000)       | <a href="#">General Cardiology</a>                  |
| True Health                   | Research/Research Grants<br>‡ Foods for Health® Portfolio of Functional Food Products: Effects on Lipid and Blood Glucose Management in Individuals Intolerant of Statin (HMG-CoA reductase inhibitor) Therapy | Significant (>= \$5,000) | <a href="#">Prevention</a>                          |

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (2)

| Non-Commercial Entity Name          | Relationship Category                               | Compensation Level | Topic Area(s)                      |
|-------------------------------------|---|--------------------|------------------------------------|
| <i>Self</i>                         |   |                    |                                    |
| Mayo Clinic CV P&T                  | Other - Task force member                           | None (\$0)         | <a href="#">General Cardiology</a> |
| Mayo Clinic Support Services, Texas | Officer, Director, Trustee, or other Fiduciary Role | None (\$0)         | <a href="#">General Cardiology</a> |

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

## Agreement

### Certified Education Attestation | Signed on 8/2/2021

[URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement](http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement)

### Confidentiality, Disclosure and Assignment Agreement | Signed on 8/2/2021

[URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement](http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement)

### Embargo | Signed on 8/2/2021

[URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement](http://disclosures.acc.org/Public/Definition/EmbargoAgreement)

### On-Going Obligation Agreement | Signed on 8/2/2021

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.